Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast

Next Previous
X
Search
Trial Profile

Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Entrectinib (Primary) ; Goserelin (Primary) ; Letrozole (Primary)
  • Indications Early breast cancer; HER2 negative breast cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms ROSALINE

    • Most Recent Events

    • 02 Dec 2024 Planned End Date changed from 1 Oct 2024 to 1 Jan 2025.
    • 02 Dec 2024 Planned primary completion date changed from 1 Aug 2024 to 1 Jan 2025.
    • 12 Jun 2024 Planned End Date changed from 1 Jul 2024 to 1 Oct 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top